AI Article Synopsis
Article Abstract
Background: Increasing rates of sexually transmitted infections (STIs) and antimicrobial resistance among young people underscore the urgent need for preventative interventions. Interventions should be evidence-based and tailored to the unique risks and needs associated with varying age, sex and sexual orientation. We used data from the Safetxt trial to explore whether young people's age, sex and sexual orientation influence (1) their risk of STI reinfection and condom use and (2) the effect of the Safetxt intervention on STI reinfection and condom use.
Methods: We conducted exploratory secondary analyses of data from the Safetxt trial that evaluated a theory-based digital sexual health intervention tailored according to sex and sexual orientation. We recruited 6248 young people with STIs from 92 UK sexual health clinics and assessed outcomes after 1 year, including the cumulative incidence of STI reinfection and condom use at last sex. We used adjusted logistic regression and margins plots to visualise effect modification.
Results: There were differences in STI reinfection and condom use by age, sex and sexuality. Age was associated with STI reinfection (OR 0.90, 95% CI 0.87 to 0.94) with evidence for interaction between age and sexuality (p<0.001). Our findings suggest that the risk of STI reinfection decreases with age among young heterosexuals but increases among men-who-have-sex-with-men (MSM). Overall, MSM had the highest likelihood of reinfection (OR 3.53, 95% CI 2.66 to 4.68) despite being more likely to use condoms (OR 1.50, 95% CI 1.18 to 1.91).Among MSM, age modified the intervention effect on condom use at 1 year with highest benefits among participants aged 16-18, moderate to minor benefits among those aged 18-21 and no effect among participants aged 22-24 years.
Conclusions: Future digital health interventions tailored for diverse sexuality groups need to target young people early enough to have an impact on sexual behaviour. Specific novel interventions are needed for older MSM.
Trial Registration Number: ISRCTN64390461.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1136/sextrans-2024-056285 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Effect of a community-based intervention for sexually transmitted infections on population-level prevalence among youth in Zimbabwe (STICH): a cluster-randomised trial.
Lancet Glob Health
January 2025
Clinical Research Department, London School of Hygiene & Tropical Medicine, London, UK; The Health Research Unit Zimbabwe, Biomedical Research and Training Institute, Harare, Zimbabwe.
Background: Young people are at particularly high risk of acquiring sexually transmitted infections (STIs). We conducted a trial to investigate the effect of a community-based intervention that included STI screening among youth on population-level prevalence of STIs in Zimbabwe.
Methods: STICH was a parallel-arm, cluster-randomised controlled trial nested within CHIEDZA, a trial of community-based integrated HIV and sexual and reproductive health services for youth in Zimbabwe.
Age, sex and sexual orientation effects in the Safetxt trial: secondary data analysis of a randomised controlled trial.
Sex Transm Infect
November 2024
Department of Medical Statistics, London School of Hygiene & Tropical Medicine Faculty of Epidemiology and Population Health, London, UK.
Background: Increasing rates of sexually transmitted infections (STIs) and antimicrobial resistance among young people underscore the urgent need for preventative interventions. Interventions should be evidence-based and tailored to the unique risks and needs associated with varying age, sex and sexual orientation. We used data from the Safetxt trial to explore whether young people's age, sex and sexual orientation influence (1) their risk of STI reinfection and condom use and (2) the effect of the Safetxt intervention on STI reinfection and condom use.
View Article and Find Full Text PDF[An STI rarely comes alone-An overview of sexually transmitted infections].
Inn Med (Heidelb)
October 2024
Klinische Infektiologie, Klinik 1 für Innere Medizin, Uniklinik Köln, Köln, Deutschland.
Sexually transmitted infections (STI) or sexually transmitted diseases (STD) can be caused by bacteria, viruses, fungi, protozoa and arthropods. The most frequent bacterial STIs include Chlamydia infections, syphilis and gonorrhea; viral STIs include herpes genitalis (herpes simplex virus 1 and 2), human papillomavirus (HPV) and human immunodeficiency virus (HIV). An empathetic medical history taking in cases of a clinical suspicion can provide important information for adequate diagnostics.
View Article and Find Full Text PDFPolysubstance Use and Related Risk Behaviors among People Who Inject Drugs in Kenya Preparing for Hepatitis C Virus Treatment.
Viruses
August 2024
Department of Medicine, Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, NY 10461, USA.
Article Synopsis
- * A study involving 95 people who inject drugs (PWID) in Nairobi and Coastal Kenya found that 70.5% reported PSU in the last 30 days, with common combinations including heroin and cannabis.
- * Despite a high engagement rate in medication-assisted treatment (MAT), participants demonstrated significant PSU and equipment sharing, suggesting a need for co-located BBI treatment within harm reduction services, specifically tailored for LMICs.
[Translated article] AEDV Expert Consensus for the Management of Syphilis.
Actas Dermosifiliogr
October 2024
Servicio de Dermatología, Fundación Jiménez Díaz, Madrid, España; Grupo investigación en ITS y VIH de la AEDV.
Article Synopsis
- Syphilis cases are on the rise in Western countries, with Spain reporting 6,613 new cases in 2021, predominantly affecting men, and showing an increasing trend since 2000.
- The clinical presentation of syphilis varies widely, with typical lesions like chancres and syphilitic roseola, as well as other atypical manifestations that can complicate diagnosis.
- Modern diagnostic methods include molecular assays and automated treponemal tests, with treatment primarily involving penicillin, especially recommended for pregnant women and individuals with HIV; follow-up testing is crucial for ensuring effective treatment and monitoring for reinfection.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!